ReviewJournal of clinical medicine2020
Nephroprotection by SGLT2 Inhibition: Back to the Future?
Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 3 syntheses or guidelines pooled it, 41 citations in OpenAlex.
- Pooled it
- Refractory IgA Nephropathy: A Challenge for Future Nephrologists.Medicina (Kaunas, Lithuania) · 2024Pooled it
- Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study.Cardiovascular diabetology · 2021Pooled it
- Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study.Open heart · 2022Trial
- SGLT2 inhibitors in hemodialysis or peritoneal dialysis patients: rationale and state-of-the art.Clinical kidney journal · 2026Review
- Review
- Efficacy and safety of dapagliflozin in patients with CKD: real-world experience in 93 Italian renal clinics.Clinical kidney journal · 2025Article
- Integrating the new pharmacological standard of care with traditional nutritional interventions in non-dialysis CKD.Journal of nephrology · 2025Review
- Favorable changes in the eGFR slope after dapagliflozin treatment and its association with the initial dip.Clinical and experimental nephrology · 2024Article
- Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities.Biomolecules · 2024Review
- Albuminuria and Serum Tumor Necrosis Factor Receptor Levels in Patients with Type 2 Diabetes on SGLT2 Inhibitors: A Prospective Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Article
- Assessment of Knowledge and Perception of Sodium-Glucose Co-transporter 2 (SGLT-2) Inhibitors Prescription among Physicians in Saudi Arabia.Current diabetes reviews · 2024Article
- Role of Estimated Glomerular Filtration Rate in Clinical Research: The Never-Ending Matter.Reviews in cardiovascular medicine · 2024Review
- The Interplay of Comorbidities in Chronic Heart Failure: Challenges and Solutions.Current cardiology reviews · 2024Review
- Retrospective analysis of the effect of SGLT-2 inhibitors on renal function in patients with type 2 diabetes in the real world.Frontiers in pharmacology · 2024Article
- Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus.European journal of nuclear medicine and molecular imaging · 2023Article
- Article
- Emerging Role of Sodium-Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease.International journal of nephrology and renovascular disease · 2023Review
- Diet and Proteinuria: State of Art.International journal of molecular sciences · 2022Review
- An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.International journal of molecular sciences · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The introduction of sodium/glucose cotransporter 2 inhibitors (SGLT2i) has opened new perspectives for the management of diabetic population at risk of or with chronic kidney disease (CKD). More important, recent, large real-world studies have repositioned the nephroprotective efficacy of SGLT2i emerged from randomized trials within the frame of effectiveness. Furthermore, the salutary effects of these agents may extend to the nondiabetic population according to the positive results of current studies. Nevertheless, the clear benefits of these agents on the prevention of organ damage contrast with their unexpected, limited use in clinical practice. One potential barrier is the acute decline in glomerular filtration rate (GFR) commonly observed at the beginning of treatment. This phenomenon is reminiscent of the early response to the traditional nephroprotective interventions, namely blood pressure lowering, dietary protein and salt restriction and the inhibition of the renin-angiotensin system. Under this perspective, the "check-mark" sign observed in the GFR trajectory over the first weeks of SGT2i therapy should renew interest on the very basic goal of CKD treatment, i.e., alleviate hyperfiltration in viable nephrons in order to prolong their function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.